Wentworth Kory James
WENTWORTH KORY JAMES, CFO, reported a transaction classified as withholding at Entrada Therapeutics, Inc. involving 1733.000000 shares for an estimated $12380.38. Reported holdings after the transaction were 117277.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 02, 2026
- Filing date
- Sep 03, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
TRDA price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- withholding Code F
- Identifier
- 0001725663-26-000007 Common Stock
- Transaction date
- Sep 02, 2026 Filed Sep 03, 2026, 09:15 PM · 1d delay
- Shares
- 1,733 sh $7.14 per share
- Estimated value
- -$12.3k Computed from shares × price
- Holdings after
- 117,277 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-12 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction. - tax_withholding-22 points
transaction_code = F
Tax withholding on vesting shares is mechanical.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Financial Officer
- F1
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax wit…
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide…
0 other transactions
0 recent txs